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331Abstracts
quency of ofﬁce-based visits was the primary driver of increased
psoriasis-speciﬁc health care costs (p = 0.02). There were no sig-
niﬁcant differences in health care costs among patients using dif-
ferent types of psoriasis medications. CONCLUSIONS: Cost
towards psoriasis medications account for most of the psoriasis-
speciﬁc health care costs. Increase in frequency of ofﬁce-based
visits seems to be the primary driver of increased psoriasis-
speciﬁc health care costs.
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OBJECTIVE: There have been tremendous advances in treat-
ment for patients with extensive psoriasis. Many of the newer
treatments have shown great promise, but at a signiﬁcant cost to
the health care system. Ofﬁce phototherapy treatments continue
to be an excellent ﬁrst choice because of high safety, good efﬁ-
cacy and relatively low cost. Unfortunately, ofﬁce phototherapy
may not be feasible for many patients. Home UVB offers another
option for these patients. The purpose of this study is to 
assess the long-term ﬁnancial cost of home UVB treatment.
METHODS: We constructed a societal cost model for owning
and operating a home UVB unit over a period of 30 years. This
model included both direct and indirect costs associated with
home treatment and periodic follow-up. These data were com-
pared to the cost of other monotherapies for extensive psoriasis.
RESULTS: The discounted present value of 30 years of treatment
with home UVB was approximately $10,000. The initial one
time cost of the home UVB device, approximately $2000, is 
only a small component of the lifetime cost. Over the same 
treatment period, methotrexate had an estimated cost of
$23,530. The cost of one year of biologic treatment exceeded the
lifetime cost of home UVB. CONCLUSIONS: Home UVB is not
for every patient with psoriasis. Highly inﬂammatory lesions or
signiﬁcant co-existent arthritis are just two of many reasons 
that systemic treatments may be required. Nevertheless, home
UVB offers a very cost-efﬁcient approach to treatment. Insurers
should make this option more available to patients with 
extensive psoriasis.
PSK5
COST-UTILITY ANALYSIS OF AMEVIVETM (ALEFACEPT) IN THE
TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE
PSORIASIS
Iskedjian M1, Barkovsky L1, Desjardins O1,Walker JH2, Dorkalam M3,
Shear N4, Einarson TR4
1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada;
2Brock University, St. Catharines, ON, Canada; 3Biogen Idec Canada
Inc, Mississauga, ON, Canada; 4University of Toronto,Toronto, ON,
Canada
OBJECTIVES: Quality of life concerns (social discomfort,
embarrassment, etc.) are an important aspect for patients 
with moderate-to-severe plaque psoriasis. Alefacept is a new 
biological found effective for treatment. This cost-utility 
analysis was conducted to compare standard therapies to ale-
facept. METHODS: A two-year Markov model was developed.
Response was assessed using the Psoriasis Area and Severity
Index Score (PASI) 75. Patient preferences were expressed in util-
ities. Treatments with high utilities represented the greatest
health improvement. Treatment comparators were methotrexate,
cyclosporine, and phototherapy (with/without acitretin). Data,
resource use, and health-state utilities were derived from litera-
ture, expert clinical opinion and a cost of illness (COI) study.
Costs (Canadian dollars) were obtained from standard published
lists. Separate Ontario Ministry of Health (MoH) and societal
(SOC) perspectives were conducted. RESULTS: In the MoH base
case, expected costs were $7,790, $9,042, $10,635, $32,859 for
methotrexate, phototherapy, cyclosporine and alefacept, respec-
tively. Response-days associated with each treatment were 175,
78, 175 and 247 days respectively. The cost of each additional
QALY (Quality-adjusted life-year), compared to methotrexate,
was $97,887. For the SOC base case, each additional QALY was
$96,426. Phototherapy and cyclosporine were dominated. These
results used the PASI 75. However, the PASI 50 may be more
clinically relevant for dermatologists and patients. Using the
PASI 50, alefacept had the highest cost and highest utility of
$92,043 (MoH) and $88,391 (SOC) per QALY. Psoriasis is a
chronic disease, and it is important to assess cost-utilities over
time. After ﬁve years, the QALY for the MoH perspective was
$31,412. SOC results were similar. Using the PASI 50 response
rates, the cost per QALY after three years was similar to that of
the PASI 75 after ﬁve years. CONCLUSION: Alefacept compares
favourably to methotrexate, the current standard of treatment,
and is cost-effective in several scenarios while cyclosporine and
phototherapy were dominated.
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OBJECTIVES: To aid in the interpretation of scores on the
QoLIAD and provide information on what represents meaning-
ful change in QoLIAD scores. METHODS: The QoLIAD is a
25-item needs-based instrument assessing the quality of life
(QoL) of individuals with atopic dermatitis (AD). It has simple
“Yes”/“No” response options and scores range from zero to 25.
Data collected from patients in a six-month, multinational, 
open-label study were analysed. Effect Size (ES), Standardised
Response Mean (SRM), the Responsiveness Statistic (RS) and
Standard Error of Measurement (SEM) were calculated. An
anchor-based Minimal Important Difference (MID); which pro-
vides an estimate of clinical meaningfulness was derived by mea-
suring QoL change accompanying changes in disease severity on
a six-point Investigator’s Global Assessment (IGA). The IGA
ranged from zero (clear) to ﬁve (very severe disease). QoLIAD
scores were also anchored to questions asking patients if they
would continue to use or recommend the study treatment.
RESULTS: In total, 264 AD patients completed the QoLIAD
(112/42% male; mean age 37 +/- 14.3; baseline mean QoLIAD
= 7.1 +/- 5.4; two-months = 5.8 +/- 5.6; six-months = 4.9 +/-
5.5). Changes from baseline were signiﬁcant (p < 0.001,
Wilcoxon test). According to ES, changes of 1.1, 2.7, and 4.3
represent small, moderate and large changes in QoLIAD scores,
respectively. One SEM = 1.71; 1.96 SEM = 3.35. Mean change
scores of patients who would deﬁnitely continue to use and def-
initely recommend product was 1.8 and 2.2, respectively. A two-
point improvement in IGA scores equated to a 2.1 (baseline
two-months) and 3.1 (baseline six-months) change in QoLIAD
scores. CONCLUSION: Distribution- and anchor-based
methods of interpreting instrument scores suggest that a change
in QoLIAD scores of between two and three can be considered
